Tumor specific growth factor detection reagent, kit and application
Through multi-antibody combination and magnetic nanoparticle coating technology, combined with chemiluminescence labeling, the sensitivity and specificity of tumor-specific growth factor detection are improved, and the problem of insufficient sensitivity and accuracy of existing detection methods is solved, achieving efficient Tumor detection.
Patent Information
- Application Number
- CN202411085508.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-15
AI Technical Summary
The existing tumor-specific growth factor (TSGF) detection kits have problems such as low sensitivity, low accuracy, narrow linear range and poor specificity, which cannot meet the needs of clinical applications.
Multi-antibody combinations, including EGF, NGF, TGF-α, TGF-β, HGF, bFGF and/or PDGF, are used to combine magnetic nanoparticle coating and chemiluminescence labeling technology to improve the sensitivity and specificity of the detection system.
The tumor detection rate has been significantly improved, and the detection performance is manifested as high sensitivity, wide linear range and high accuracy, meeting the needs of clinical testing and replacing existing detection methods.
Smart Images

Figure BDA0004985076090000091 
Figure BDA0004985076090000101 
Figure BDA0004985076090000111
Abstract
Description
Technical Field
[0001] The invention belongs to the field of immunological analysis and detection, and particularly relates to a tumor-specific growth factor detection reagent, a kit containing the detection reagent, and use of the detection reagent in preparing a kit for detecting tumors. Background Art
[0002] Tumor-specific growth factor (TSGF) belongs to the large category of non-blood cell growth factors with a small relative molecular mass. It is a general term for several internationally recognized carbohydrate substances and metabolites related to the growth of malignant tumors, including epidermal growth factor (EGF), nerve growth factor (NGF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor α and β (TGF-α, TGF-β), human bone growth factor (HSGF) and angiopoietin (ANG).
[0003] TSGF is a marker secreted by tumor cells and is related to tumor growth and vascular survival. Qi Famei, Wei Lianhua and others found that the diagnostic sensitivity of TSGF in intestinal malignant tumors is 80.00%, the diagnostic sensitivity of gastric malignant tumors is 76.19%, the diagnostic sensitivity of lung malignant tumors is 82.65%, the diagnostic sensitivity of liver cancer and cirrhosis is 96.55%, the diagnostic sensitivity of bile duct cancer is 71.43%, and the diagnostic sensitivity of ovarian cancer is 52.59%. TSGF has become a widely used tumor screening and recurrence monitoring indicator due to its wide tumor spectrum and high sensitivity.
[0004] TSGF has certain value in monitoring tumor growth and recurrence. However, the common TSGF determination kits currently have problems such as low sensitivity, low accuracy, narrow linear range, and poor specificity that cannot meet the requirements of clinical application. Summary of the invention
[0005] The invention provides a tumor specific growth factor detection reagent, which can improve the sensitivity and specificity of the TSGF detection system.
[0006] In order to achieve the above object, the present invention adopts the following technical solution:
[0007] In a first aspect, the present invention provides a tumor-specific growth factor detection reagent, comprising:
[0008] The first antibody comprises at least two of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF and / or PDGF, and the molar ratio of the above antibodies is (1-2):(1-2):(1-2):(1-2):(1-2):(1-2):(1-2); the concentration of the first antibody is 0.3-10 μg / mL.
[0009] In some embodiments, the first antibody comprises at least three of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF, and / or PDGF.
[0010] In some embodiments, the first antibody comprises at least four of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF, and / or PDGF.
[0011] In some embodiments, the first antibody comprises at least five of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF, and / or PDGF.
[0012] In some embodiments, the first antibody comprises at least six of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF, and / or PDGF.
[0013] In some embodiments, the first antibody consists of EGF, NGF, TGF-α, TGF-β, HGF, bFGF, and PDGF.
[0014] In some embodiments, the first antibody consists of EGF, NGF, TGF-β, HGF, bFGF, and PDGF.
[0015] In a second aspect, the present invention provides a tumor-specific growth factor detection kit, comprising:
[0016] A first reagent, comprising a solid phase carrier and the above-mentioned detection reagent, wherein the first antibody in the detection reagent is coated on the solid phase carrier to form a solid phase carrier coating, and the concentration of the solid phase carrier coating is 0.08-0.4 mg / mL;
[0017] The second reagent comprises a second antibody, the components of the second antibody are the same as those of the first antibody, the concentration of the second antibody is 0.04-0.3 μg / mL, and the second antibody is labeled with a chemiluminescent agent.
[0018] In some embodiments, the solid phase carrier comprises one or more combinations of magnetic nanoparticles, gold nanoparticles or microplates. Preferably, the solid phase carrier is magnetic nanoparticles.
[0019] Furthermore, the magnetic nanoparticles are superparamagnetic nanospheres, and the particle size of the superparamagnetic nanospheres is 1000nm-3000nm.
[0020] In some embodiments, the first reagent also includes a solid phase carrier diluent, and the volume ratio of the solid phase carrier coating to the solid phase carrier diluent is 1:50-1:10.
[0021] In some embodiments, the solid phase carrier diluent is a magnetic nanoparticle diluent, and the magnetic nanoparticle diluent includes 0.02M-0.1M phosphate buffer, 0.5%-10% protein stabilizer and 0.01-0.5% surfactant; the pH value of the phosphate buffer is 6.8-7.4; the protein stabilizer is one or more combinations of bovine serum albumin, calf serum, goat serum, casein, sucrose, and trehalose; the surfactant is one or more combinations of Tween 20, Tween 80, Triton X-100, and S9.
[0022] In some embodiments, the detection kit further includes a calibrator and a quality control product, wherein the calibrator is obtained by diluting the antigen component corresponding to the first antibody, and the quality control product is obtained by diluting the antigen component corresponding to the first antibody.
[0023] In some embodiments, the calibrator diluent comprises 0.01M-0.1M phosphate buffer, 0.5%-10% stabilizer and 0.01%-0.5% surfactant; the stabilizer is one or more combinations of bovine serum albumin, calf serum, goat serum, casein, sucrose, and trehalose; the surfactant is one or more combinations of Tween 20, Tween 80, Triton X-100, and S9.
[0024] In some embodiments, the concentration of the antigen component in the calibrator and quality control material is 0.1-300 ng / mL.
[0025] In some embodiments, the chemiluminescent agent includes any one of an acridinium ester, an acridinium ester derivative, terpyridine ruthenium, luminol, a luminol derivative, isoluminol, AMPPD, an oxalate, a peroxyoxalate compound, a dioxetane, or a dioxetane compound.
[0026] In some embodiments, the chemiluminescent agent comprises an acridinium ester.
[0027] Furthermore, the detection kit also includes an stimulator, which includes an stimulatory solution A and an stimulatory solution B. The stimulatory solution A includes H2O2, ethanol and Tween 20, and the stimulatory solution B includes sodium hydroxide, ethanol and Triton X-100.
[0028] In some embodiments, the second reagent further includes a chemiluminescent agent diluent, and the volume ratio of the second antibody labeled with the chemiluminescent agent to the chemiluminescent agent diluent is 1:500-1:200.
[0029] In some embodiments, the chemiluminescent agent diluent is an acridinium ester diluent, which includes 0.02M-0.1M Tris buffer, 0.5%-10% stabilizer and 0.01%-0.5% surfactant; the stabilizer is one or more combinations of bovine serum albumin, calf serum, goat serum, casein, sucrose, and trehalose; the surfactant is one or more combinations of Tween 20, Tween 80, Triton X-100, and S9.
[0030] In a third aspect, the present invention provides a method for preparing a tumor-specific growth factor detection kit, including: a method for preparing a first antibody coated with magnetic nanoparticles and a method for preparing a second antibody labeled with an acridinium ester.
[0031] The method for preparing the first antibody coated with magnetic nanoparticles comprises the following steps:
[0032] (a) obtaining magnetic nanoparticles; (b) using magnetic nanoparticles to individually coat each primary antibody; and (c) mixing magnetic nanoparticles coated with multiple primary antibodies.
[0033] The method for preparing the acridinium ester-labeled second antibody comprises the following steps:
[0034] (a) Individual secondary antibodies are labeled with acridinium esters; (b) labeling is terminated by adding acridinium ester termination buffer; (c) multiple secondary antibodies labeled with acridinium esters are mixed after dialysis is completed.
[0035] In some embodiments, the method for preparing the first antibody coated with magnetic nanoparticles comprises the following steps:
[0036] (1) washing the magnetic nanoparticles with a coating buffer, enriching them with a magnet, removing the reaction solution, and washing them again with a coating buffer;
[0037] (2) The washed magnetic nanoparticles were sequentially added with coating buffer, activator 1 and activator 2, mixed and then placed in a mixer for activation at room temperature for 30 min; after the reaction was completed, the magnetic nanoparticles were enriched with a magnet, the reaction solution was sucked off and then washed twice with coating buffer;
[0038] (3) Add coating buffer to resuspend, then add the required amount of various antibodies of EGF, NGF, TGF-α, TGF-β, HGF, bFGF, and PDGF, and place in a mixer for coating at room temperature for 3 hours;
[0039] (4) Re-enrich the above product with a magnet, remove the reaction solution and wash with coating buffer three times, add blocking agent, place in a mixer and block at room temperature for 2 h;
[0040] (5) Re-enrich the product obtained in step (4) using a magnet, remove the reaction solution, wash three times with coating buffer, add magnetic bead diluent, and obtain a magnetic bead coating.
[0041] (6) Mixing magnetic beads coated with various antibodies in a certain ratio.
[0042] In some embodiments, Activator 1 is EDC and Activator 2 is S-NHS.
[0043] In some embodiments, the coating buffer is MES buffer with a pH value of 4.0-6.0.
[0044] In some embodiments, the blocking agent comprises phosphate buffered saline, 0.5-2% bovine serum albumin, and 0.02-0.2% preservative.
[0045] In some embodiments, the mixing ratio of multiple antibody coatings is (1-2):(1-2):(1-2):(1-2):(1-2):(1-2):(1-2):(1-2).
[0046] In some embodiments, the method for preparing the acridinium ester marker comprises the following steps:
[0047] (1) taking an acridinium ester labeling buffer, EGF, NGF, TGF-α, TGF-β, HGF, bFGF, PDGF monoclonal antibodies and an acridinium ester mother solution, mixing them evenly and performing a labeling reaction at room temperature in the dark;
[0048] (2) After the labeling reaction, an acridinium ester conjugate is obtained, and an acridinium ester termination buffer is added to the acridinium ester conjugate, mixed evenly, and reacted at room temperature in the dark;
[0049] (3) dialyzing the reaction product of step (2) using an acridinium ester dialysis buffer;
[0050] (4) After dialysis is completed, glycerol and a protective agent are added to the reaction product and mixed until a homogeneous phase is obtained to obtain an acridinium ester labeled substance;
[0051] (5) Mixing acridine ester coatings labeled with various antibodies in a certain ratio.
[0052] In some embodiments, the acridinium ester termination buffer comprises 0.02M-0.1M buffer solution, 0.05-0.2M inorganic salt and 0.5-2% amino acid; the buffer solution is a PB buffer solution with a pH value of 7.0-9.0; and the amino acid is one or more combinations of lysine, glycine or alanine.
[0053] In some embodiments, the ratio of acridinium ester coatings for multiple antibody labels is (1-2):(1-2):(1-2):(1-2):(1-2):(1-2):(1-2).
[0054] In a fourth aspect, the present invention provides a chemiluminescent immunoassay method, comprising the following steps:
[0055] Test calibrators and create master curves;
[0056] Calibrate the fully automatic chemical immunoassay analyzer with the calibrator to obtain a calibration curve;
[0057] Test the quality control product. If the test value is within the specified target value range, the sample test can be carried out;
[0058] The instrument takes the sample to be tested, uses the above-mentioned kit to perform immune reaction, adds the stimulating solution, enters the fully automatic immunoassay system, measures the luminescent signal, and obtains the concentration of tumor-specific growth factor in the sample through the calibration curve.
[0059] Furthermore, the luminescent agent of the above-mentioned kit is acridinium ester, and the stimulator includes stimulating solution A and stimulating solution B; the stimulating solution A includes H2O2, ethanol and Tween 20, and the stimulating solution B includes sodium hydroxide, ethanol and Triton X-100.
[0060] In some embodiments, the above solution further comprises: 0.02-0.2% preservative.
[0061] The addition of preservatives can prevent the growth of microorganisms from adversely affecting the quality of the kit. Any substance that can inhibit the growth of microorganisms can be used as the preservative of the present invention. Preferably, the preservative is one of BND and Proclin 300 or a combination of the two.
[0062] The stabilizer added in the present invention protects the activity of the antibody / antigen, increases the stability of each component in the kit, and prolongs the shelf life of the product.
[0063] The role of adding a surfactant in the present invention is to promote the uniform dispersion of various components in the test kit system and various substances in the test sample and to improve the detection precision, thereby ensuring the reproducibility of the results.
[0064] In a fifth aspect, the present invention provides use of the above-mentioned detection reagent in preparing a kit for detecting tumors.
[0065] Compared with the prior art, the technical effects achieved by the present invention include:
[0066] The detection reagent of the present invention adopts a combination of multiple antibodies. Since TSGF is a polypeptide substance produced by tumor cells and is related to tumor growth and vascular survival, the detection of the multiple antibody combination can improve the tumor detection rate, that is, it can improve the sensitivity of the detection system; the detection kit of the present invention has the advantages of high analytical sensitivity, wide linear range and high accuracy, and has better detection performance; at the same time, the antibodies selected by the chemiluminescent immunoassay method of the present invention have good specificity for tumors, so the detection system has good specificity, can replace the existing detection methods, and meet the needs of clinical detection. DETAILED DESCRIPTION
[0067] The technical solutions in the embodiments are described clearly and completely below. Obviously, the embodiments described below are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0068] It should be understood that when used in this specification and the appended claims, the terms "include" and "comprises" indicate the presence of described features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or combinations thereof.
[0069] It should also be understood that the terms used in this description of the embodiments of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the embodiments of the present invention. As used in the description of the embodiments of the present invention and the appended claims, unless the context clearly indicates otherwise, the singular forms of "a", "an" and "the" are intended to include plural forms.
[0070] It should also be understood that, unless otherwise specified, the percentage sign % used in the present invention represents the mass fraction of the solute, specifically the ratio of the mass of the solute to the total mass of the solution.
[0071] Example 1
[0072] A tumor-specific growth factor detection kit comprises a first antibody coated with superparamagnetic nano-microspheres and a second antibody labeled with acridinium ester, wherein the first antibody and the second antibody are composed of EGF and TGF-β.
[0073] Preparation of superparamagnetic nanospheres coated with the first antibody
[0074] The preparation process of the first antibody superparamagnetic nanosphere coating is as follows:
[0075] (1) Take 4 mg of superparamagnetic nanospheres with a particle size of 1600 nm, add them to 1 mL of coating buffer, and use a magnet to enrich the superparamagnetic nanospheres, absorb the reaction solution, and wash twice with coating buffer;
[0076] (2) Add the washed superparamagnetic nanospheres to the coating buffer, add 0.8 mg of activator 1 (EDC) and 0.8 mg of activator 2 (S-NHS), and place in a mixer for activation at room temperature for 30 min; after the reaction is completed, enrich with a magnet, remove the reaction solution, and wash twice with the coating buffer;
[0077] (3) Add coating buffer to resuspend, then add the required amount of EGF and TGF-β antibodies respectively to make the final concentration of the antibody solution 20 μg / mL, place in a mixer and coat at room temperature for 3 h;
[0078] (4) Re-enrich the above product with a magnet, remove the reaction solution and wash with coating buffer three times, add blocking agent, place in a mixer and block at room temperature for 2 h;
[0079] (5) Re-enriching the product obtained in step (4) with a magnet, removing the reaction solution, washing with coating buffer for 3 times, adding magnetic bead diluent, and obtaining antibody-coated superparamagnetic nanospheres.
[0080] In the above preparation process, the coating buffer is MES buffer with a pH value of 5.0 and a concentration of 0.05M; the blocking agent includes phosphate buffer, 1% bovine serum albumin and 0.1% preservative; and the magnetic bead diluent includes 0.02M phosphate buffer, 1% bovine serum albumin, 0.1% Tween 80 and 0.1% Proclin300.
[0081] Preparation of the first antibody superparamagnetic nanosphere coating
[0082] The two antibody-coated superparamagnetic nanospheres were mixed in a ratio of 1:1 and added to the magnetic bead diluent to obtain the first reagent, wherein the final concentration of the superparamagnetic nanospheres was 0.3 mg / mL.
[0083] Preparation of acridinium ester labelled secondary antibodies
[0084] 1) Labeling: for each 1 ml of acridinium ester marker, 300 μl of acridinium ester labeling buffer, 20 μg of EGF and TGF-β monoclonal antibodies, and 0.008 mM acridinium ester stock solution were added to a centrifuge tube, and the mixture was inverted to mix well, and the mixture was reacted for 30 min at room temperature in the dark;
[0085] 2) Termination: After 30 minutes of labeling reaction, an acridinium ester conjugate is obtained. The acridinium ester termination buffer is added to the acridinium ester conjugate in an amount equal to the reaction volume × 0.1. The mixture is mixed by manual inversion and reacted at room temperature in the dark for 30 minutes.
[0086] 3) Dialysis, transfer all the above-obtained products into a dialysis bag, clamp the two ends with dialysis clips, clamp (tighten with a rubber band), and confirm that there is no leakage; measure 2L of acridinium ester dialysis buffer into a beaker, put the dialysis bag containing the marker into the beaker, place the beaker on a stirrer, start the stirrer, place in a 2°C refrigerator, avoid light, stir, replace the acridinium ester dialysis buffer every 2 hours, and replace the dialysate 3 times in total;
[0087] 4) Take out the beaker, take out the dialysis bag, transfer all the markers into a new centrifuge tube, add 60% glycerol, add 0.1% BSA to the centrifuge tube, mix gently until homogeneous, and store at -20°C away from light.
[0088] The acridinium ester labeling buffer comprises 0.1M PB buffer solution at pH 8.0, 0.15M NaCl and 0.1% Proclin300; the acridinium ester termination buffer comprises 0.1M PB buffer solution at pH 8.0, 2% lysine and 0.1% Proclin300; the acridinium ester dialysis buffer is 20mM PBS buffer.
[0089] Preparation of secondary antibody acridinium ester label
[0090] The above two second antibody acridinium ester labels were mixed in a ratio of 1:1 to prepare a second antibody acridinium ester label, and added into the acridinium ester diluent at 1 / 300 (v / v) to obtain a second reagent.
[0091] The acridinium ester diluent comprises: 0.02M Tris buffer, 10% goat serum, 2% trehalose, 0.1% Tween 20 and 0.1% Proclin300.
[0092] Preparation of calibrators and quality control products
[0093] The calibrator dilution was used as calibrator 1;
[0094] Dilute EGF and TGF-β antigens to 1 ± 0.2 ng / mL using calibrator diluent as calibrator 2;
[0095] Dilute EGF and TGF-β antigens to 100 ± 20 ng / mL with calibrator diluent as calibrator 3;
[0096] Dilute EGF and TGF-β antigens to 5 ± 1 ng / mL with calibrator diluent as quality control 1;
[0097] Dilute EGF and TGF-β antigens to 50±10 ng / mL using calibrator diluent as quality control product 2.
[0098] Preparation of stimulating solution
[0099] The stimulating solution includes stimulating solution A and stimulating solution B. The stimulating solution A includes 1% H2O2 solution, 0.25% ethanol and 0.5% Tween 20, and the stimulating solution B includes 1M sodium hydroxide, 0.25% ethanol and 0.5% Triton X-100.
[0100] Example 2
[0101] The difference from Example 1 is that the first antibody and the second antibody components are EGF, NGF, TGF-β and PDGF, and the ratio of the above antibodies is 1:1:1:1; the calibrators and quality controls use EGF, NGF, TGF-β and PDGF antigens.
[0102] Example 3
[0103] The difference from Example 1 is that the first antibody and the second antibody components are EGF, NGF, TGF-β, HGF, bFGF and PDGF, and the ratio of the above antibodies is 1:1:1:1:1:1; the calibrators and quality control products use EGF, NGF, TGF-β, HGF, bFGF and PDGF antigens.
[0104] Example 4
[0105] The difference from Example 1 is that the first antibody and the second antibody components are EGF, NGF, TGF-β, HGF, bFGF and PDGF, and the ratio of the above antibodies is 1:2:1:1:1:1; the calibrators and quality control products use EGF, NGF, TGF-β, HGF, bFGF and PDGF antigens.
[0106] Example 5
[0107] The difference from Example 1 is that the first antibody and the second antibody components are EGF, NGF, TGF-α, TGF-β, HGF, bFGF and PDGF, and the ratio of the above antibodies is 1:1:1:1:1:1:1:1; the calibrators and quality control products use EGF, NGF, TGF-α, TGF-β, HGF, bFGF and PDGF antigens.
[0108] Experiment 1: Comparative Example 1 (the first antibody and the second antibody are EGF) and Comparative Example 2 (the first antibody and the second antibody are TGF-β) were set up. The kits prepared in the comparative example and different embodiments were used to detect 128 normal negative serum, 42 breast cancer patient serum samples, and 38 lung cancer patient serum samples, respectively, to examine the specificity and sensitivity of the kit. Sensitivity = number of positive samples detected by the kit / number of positive samples for pathological diagnosis × 100%, specificity = number of negative samples detected by the kit / number of negative samples of normal people × 100%. The results are shown in Table 1.
[0109] Table 1: Sensitivity and specificity of the kits prepared with different antibody combinations for the detection of breast cancer and lung cancer
[0110]
[0111]
[0112] From the results in Table 1, it can be seen that compared with Comparative Examples 1 and 2, increasing the types of antibodies has a better effect on improving the sensitivity of the reagent, but when the types of antibodies exceed 6, the sensitivity and specificity of the reagent will decrease. Among them, the specificity of Example 4 is 95.3%, the detection rate for breast cancer is 95.2%, and the detection rate for lung cancer is 92.1%, which is the best effect among all combinations. The difference between Example 4 and Example 3 lies in the proportion of nerve growth factor (NGF) in the reagent. Increasing the proportion of NGF can improve the sensitivity of the reagent. The main reason is that the antibody activity of NGF is lower than that of other antibodies, and the dosage needs to be increased to achieve better results.
[0113] Experiment 2: Comparison kit 1 (turbidimetric method: R1 reagent is buffer, R2 reagent is latex microspheres coated with EGF antibody), comparison kit 2 (turbidimetric method: R1 reagent is buffer, R2 reagent is latex microspheres coated with EGF, NGF, TGF-β, HGF, bFGF and PDGF antibodies) and comparison kit 3 (colorimetric method: specific growth factor determination kit produced by Anhui Ipronocon Biotechnology Co., Ltd.) were set up. 128 normal human negative sera, 42 breast cancer patient serum samples, and 38 lung cancer patient serum samples were tested using comparison kits 1, 2 and 3, respectively. The specificity and sensitivity of each kit were investigated, and compared with the specificity and sensitivity of Examples 3 and 4 in Table 1. The results are shown in Table 2.
[0114] Table 2: Sensitivity and specificity of TSGF kits with different detection mechanisms and antibody components for breast cancer and lung cancer detection
[0115]
[0116] From the results in Table 2, the sensitivity of turbidimetric method with 6 antibodies to breast cancer and lung cancer is worse than that of 1 antibody, but for the same 6 antibodies, the sensitivity of turbidimetric method is not as good as that of chemiluminescence method. The sensitivity and specificity of colorimetric method to breast cancer and lung cancer are not as good as that of chemiluminescence method.
[0117] Based on the results of Experiment 1 and Experiment 2, it can be concluded that the kit using the above-mentioned TSGF antibody combination has the advantages of high sensitivity and high specificity, and the chemiluminescent immunoassay kit using a multi-antibody combination has the highest sensitivity and specificity.
[0118] Experiment 3: Evaluation of specific growth factor kit (chemiluminescent immunoassay) The kit prepared in Example 4 was used to evaluate the following performance.
[0119] (1) Analytical sensitivity (detection limit)
[0120] The analytical sensitivity (detection limit) of the kit provided by the present invention is no more than 0.1 ng / mL; 5 samples with concentrations close to the detection limit of the kit (numbered: LoD1-LoD5) were selected, each sample was tested 5 times, and a sample with a concentration of 0 was tested at the same time. The results are shown in Tables 3-4. The test results of this reagent have no more than 3 values less than the blank limit, which meets the requirements.
[0121] Table 3: Blank limit test results (concentration: ng / mL)
[0122]
[0123] Table 4: Detection limit test results (concentration: ng / mL)
[0124]
[0125]
[0126] (2) Linear range
[0127] The linear correlation coefficient r value of the kit provided by the invention is greater than 0.9900 in the range of 0.1-300 ng / mL, and the test results are shown in Table 5.
[0128] Table 5: Linear range test results
[0129]
[0130] (3) Repeatability
[0131] The repeatability of this reagent is within 5%. Sample 1 and sample 2 were tested 10 times respectively, and the results are shown in Table 6.
[0132] Table 6: Repeatability results
[0133]
[0134]
[0135] (4) Accuracy
[0136] The accuracy deviation of this reagent is within ±6%. Accuracy measurement refers to adding a known amount of antigen to the sample diluent, measuring the concentration value after addition and comparing it with the theoretical concentration value, and calculating the deviation. The test results are shown in Table 7.
[0137] Table 7: Accuracy test results
[0138]
[0139] According to the results of Tables 3 to 7, the detection kit provided by the present invention has the advantages of high analytical sensitivity, wide linear range, good repeatability, high accuracy, and low cost, which can meet the needs of current clinical testing.
[0140] In the above embodiments, the description of each embodiment has its own emphasis. For parts that are not described in detail in a certain embodiment, reference can be made to the relevant descriptions of other embodiments.
[0141] The above is a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of various equivalent modifications or replacements within the technical scope disclosed by the present invention, and these modifications or replacements should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.
Claims
1. A tumor-specific growth factor detection reagent, characterized in that: include: A first antibody, wherein the first antibody comprises at least two of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF and / or PDGF, and the molar ratio of the above antibodies is (1-2):(1-2):(1-2):(1-2):(1-2):(1-2); The concentration of the first antibody is 0.3-10 μg / mL.
2. The detection reagent according to claim 1, characterized in that The first antibodies include at least four of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF and / or PDGF.
3. The detection reagent according to claim 2, characterized in that The first antibodies include at least five of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF and / or PDGF.
4. The detection reagent according to claim 3, characterized in that The first antibodies include at least six of the following antibodies: EGF, NGF, TGF-α, TGF-β, HGF, bFGF and / or PDGF.
5. The detection reagent according to claim 4, characterized in that The first antibody consists of EGF, NGF, TGF-β, HGF, bFGF and PDGF.
6. A tumor-specific growth factor detection kit, characterized in that: include: A first reagent, comprising a solid phase carrier and the detection reagent according to any one of claims 1 to 5, wherein the first antibody in the detection reagent is coated on the solid phase carrier to form a solid phase carrier coating, and the concentration of the solid phase carrier coating is 0.08-0.4 mg / mL; The second reagent comprises a second antibody, the components of the second antibody are the same as those of the first antibody, the concentration of the second antibody is 0.04-0.3 μg / mL, and the second antibody is marked with a luminescent agent.
7. The detection kit according to claim 6, characterized in that The detection kit also includes: The calibrator and the quality control product are obtained by diluting the antigen component corresponding to the first antibody, and the quality control product is obtained by diluting the antigen component corresponding to the first antibody.
8. The detection kit according to claim 6, characterized in that The luminescent agent includes a chemiluminescent agent.
9. The detection kit according to any one of claim 6, characterized in that The solid phase carrier is one or more combinations of magnetic nanoparticles, gold nanoparticles or microporous plates.
10. Use of the detection reagent according to any one of claims 1 to 5 in preparing a kit for detecting tumors.
